Supplemental Data and Materials: Understanding JAK Inhibitor Toxicity: Is the Off-Target Kinome a Missing Piece of the Puzzle?
Description
The Appendix contains the full results of the Chemical Similarity Ensemble Approach (SEA) analysis for all JAK inhibitors included in this study. This includes FDA-approved agents (ruxolitinib, tofacitinib, baricitinib, abrocitinib, upadacitinib, ritlecitinib) and clinical-stage compounds (povorcitinib). For each molecule, SEA-generated lists of statistically significant predicted off-target kinase interactions are provided in separate supplemental tables (Tables S2–S8), including the target protein, interaction p-value, and known functional role of the kinase where available. These data offer a detailed view of the potential off-target kinome landscape and support the discussion of mechanistic hypotheses proposed in the main text regarding JAK inhibitor tolerability and toxicity.
Files
Institutions
- Vanderbilt University Medical Center